StockData
Werewolf Therapeutics, Inc. logo

Werewolf Therapeutics, Inc. (HOWL) stock

HOWLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.95−0.04 (-3.97%)

Close on Nov 20, 2026Market cap $46.00MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
$46.00M
P/E ratio
–
Price to sales
–
Price to book
2.82
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$34.61M
EPS, diluted
-$0.72
Free cash flow
-$60.29M
Book value per share
$0.34
Diluted shares
49M

Trading

Next earnings
Q3 FY2026, expected soon
Previous close
$0.99
Open
$0.95
Day's range
$0.93 – $0.99
Volume
374,029
Average volume (20 days)
453,367
Beta (5 years)
1.09
52-week range
$0.27 – $1.20
RSI (14 days)
43.4
Volatility (1 year)
141.7%
Relative volume
0.08×
WACC
10.5%

Market cap history

Month-end market cap since 2021, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 20, 2026. The S&P 500 is measured by the SPY fund.

PeriodHOWLS&P 500DifferenceHOWL per yearS&P 500 per year
1 month-9.8%-10.3%+0.5 pts
3 months+119.5%-9.3%+128.8 pts
Year to date+49.4%+1.9%+47.5 pts
1 year+10.8%+6.9%+3.9 pts
3 years-61.7%+57.5%−119.1 pts-27.4%+16.3%
5 years-94.1%+57.3%−151.4 pts-43.2%+9.5%

Seven years at a glance

Fiscal years 2019 to 2025 and trailing twelve months, USD

Operating income

-$31.26M

Net income

-$34.61M

EPS, diluted

-$0.72

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Werewolf Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Werewolf Therapeutics

Pharmaceutical Preparations

Werewolf Therapeutics is a clinical-stage biopharmaceutical company that designs and develops conditionally activated therapeutics to stimulate the immune system for treating cancer and other immune-mediated conditions. Using its proprietary PREDATOR platform, the company engineers molecules known as INDUKINE and INDUCER therapies, which function as inactive prodrugs systemically and activate selectively within the tumor microenvironment. Its lead product candidates include WTX-124, a conditionally activated Interleukin-2 therapy being evaluated in clinical trials for solid tumors, and WTX-330, an Interleukin-12 molecule being evaluated in clinical studies for advanced or metastatic solid tumors or lymphoma. The company also advances preclinical candidates and partners programs, including licensing rights for JZP898 to Jazz Pharmaceuticals Ireland Limited.

Company profile, executives and history

Werewolf Therapeutics stock: common questions

What is Werewolf Therapeutics's stock price?

HOWL closed at $0.95 on Nov 20, 2026, down 3.97% on the day. Over the past 52 weeks it traded between $0.27 and $1.20.

What is Werewolf Therapeutics's market cap?

Werewolf Therapeutics was worth $46.00M at the close on Nov 20, 2026: the share price times the diluted shares outstanding.

What is HOWL's P/E ratio?

Werewolf Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.72), so it has no meaningful P/E ratio.

Does Werewolf Therapeutics pay a dividend?

No. Werewolf Therapeutics has not paid a cash dividend over the last twelve months.

When does Werewolf Therapeutics report earnings next?

Werewolf Therapeutics's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.

How has HOWL stock performed over the past year?

Including dividends, HOWL returned +10.8% over the past year, against +6.9% for the S&P 500.

How many HOWL shares are sold short?

2M shares were sold short at the latest FINRA report, 5.81% of the float, or 6.4 days of average trading volume.

Who are Werewolf Therapeutics's competitors?

Companies most similar to Werewolf Therapeutics by business, industry and size include NKTR, CTMX, CRVS, PRLD, PLRX.

See a number that looks wrong?